立方制药：达格列净二甲双胍缓释片药品注册上市许可申请获受理

Core Viewpoint - The company, Lianfang Pharmaceutical, has received a notice of acceptance for the drug registration application of Dapagliflozin Metformin Extended-Release Tablets from the National Medical Products Administration, indicating progress in bringing this combination diabetes medication to market [1] Group 1: Product Details - Dapagliflozin Metformin Extended-Release Tablets are a fixed-dose combination formulation that includes Dapagliflozin, an SGLT2 inhibitor, and Metformin, a biguanide, which work synergistically to control blood sugar levels [1] - Dapagliflozin lowers blood sugar by promoting urinary glucose excretion, while Metformin primarily reduces hepatic glucose output and improves insulin sensitivity [1] - This combination aims to provide more comprehensive and effective blood sugar control for adult patients with type 2 diabetes [1] Group 2: Market Context - The product is co-developed by Bristol-Myers Squibb Company and AstraZeneca AB, indicating a collaboration between major pharmaceutical companies [1] - As of the date of the announcement, eight other companies have received approval for similar products in the domestic market, highlighting competitive dynamics in the diabetes medication sector [1]